compounding tirzepatide fda group sues for removing obesity drug from shortages list FDA Announces End To Compounded

The small resting heart rate increase from the glucagon arm is real but minor for healthy hearts, comparable to a cup of coffee

Some of the most common include rheumatoid arthritis (attacking joint tissues), Hashimotos thyroiditis (affecting thyroid function), multiple sclerosis (targeting nerve myelin), psoriasis (affecting skin cells), inflammatory bowel diseases like Crohns and ulcerative colitis (involving digestive tract tissues), lupus (potentially affecting multiple organs), and type 1 diabetes (targeting insulin-producing pancreatic cells)

If you have recent labs (within 12 months), you can upload them

As shortages abate, FDAs time-boxed enforcement discretion for compounded semaglutide/tirzepatide ended in spring 2025, pushing patients and payers back to branded pathways and putting a premium on compliant, high-throughput operations